2019 Shaffer Research Grants

For information about Shaffer Grants and research reports prior to 2013, please contact Glaucoma Research Foundation.

Spacing: small

2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013

Spacing: small
Steven Barnes, Phd

Steven Barnes, PhD

Doheny Eye Institute
Funded by Roberta and Robert H. Feldman
Project: Functional Resilience of Retinal Ganglion Cells During Mitochondrial Dysfunction
Summary: The production of energy in retinal ganglion cells is accompanied by metabolic byproducts, many of which are damaging to cellular function.
Adnan Dibas, Phd

Adnan Dibas, PhD

North Texas Eye Research Institute
Funded by The Edward Joseph Daly Foundation
Project: Endothelin Converting Enzyme Knockdown is Neuroprotective in Glaucomatous Neuropathy
Summary: Very little is known about how and why the optic nerve is progressively damaged in glaucoma.
Daniel M. Lipinski, Phd

Daniel M. Lipinski, PhD

Medical College of Wisconsin
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Development of rAAV Vector Technologies to Facilitate Topical Gene Delivery to the Cornea
Summary: New genetic material can be delivered to cells of the cornea via injection of a viral vector into in to the front chamber of the eye.
Biraj Mahato, Phd

Biraj Mahato, PhD

University of North Texas Health Science Center
Funded by The Frank Stein and Paul S. May Grants for Innovative Glaucoma Research
Project: Chemically Reprogrammed Retinal Ganglion Cell Therapy to Treat Glaucomatous Neuropathy
Summary: Retinal ganglion cell (RGC) death is the hallmark for glaucomatous damage leading to irreversible vision loss and no curative treatments are available.
Pierre Mattar, Msc, Phd

Pierre Mattar, MSc, PhD

Ottawa Hospital Research Institute
Funded by Carolyn and Richard Sloane
Project: Programming and Reprogramming for Retinal Ganglion Cell Replacement Therapy
Summary: Although glaucoma is frequently treatable with medication or surgery, a large proportion of afflicted individuals are diagnosed too late to prevent the death of key retinal neurons, which are called retinal ganglion cells (RGCs).
Lauren Katie Wareham, Phd

Lauren Katie Wareham, PhD

Vanderbilt University Medical Center
Funded by Dr. James and Elizabeth Wise
Project: Investigating the Role of the NO-GC-1-cGMP Signaling Pathway in Glaucoma
Summary: The GC1 murine model of glaucoma aligns well with the pathophysiology seen in primary open angle glaucoma patients; the disease progresses with age, and mice have moderately elevated IOP, leading to degeneration of the optic nerve.
Pete A. Williams, Phd

Pete A. Williams, PhD

Karolinska Institutet
Funded by The Dr. Henry A. Sutro Family Grant for Research
Project: Targeting Neuronal Mitochondria for Neuroprotection in Glaucoma
Summary: Current glaucoma treatment strategies only target IOP, the principal treatable risk factor.